Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Abstract

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A′, R 1 , R 2 and R 3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

1 - 72 . (canceled) 
     
     
         73 . A method of treating an HIV infection in a human having or at risk of having the infection comprising administering to the human a therapeutically effective amount of a compound selected from 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of two additional therapeutic agents, wherein the first additional therapeutic agent is selected from tenofovir alafenamide, tenofovir alafenamide hemifumarate, and tenofovir alafenamide fumarate, and the second additional therapeutic agent is emtricitabine. 
       
     
     
         74 . The method of  claim 73 , wherein the first additional therapeutic agent is tenofovir alafenamide. 
     
     
         75 . The method of  claim 73 , wherein the first additional therapeutic agent is tenofovir alafenamide hemifumarate. 
     
     
         76 . The method of  claim 73 , wherein the first additional therapeutic agent is tenofovir alafenamide fumarate. 
     
     
         77 . A method of treating an HIV infection in a human having or at risk of having the infection comprising administering to the human a pharmaceutical composition comprising a compound selected from 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, two additional therapeutic agents, and a pharmaceutically acceptable excipient, wherein the first additional therapeutic agent is selected from tenofovir alafenamide, tenofovir alafenamide hemifumarate, and tenofovir alafenamide fumarate, and the second additional therapeutic agent is emtricitabine. 
       
     
     
         78 . The method of  claim 77 , wherein the first additional therapeutic agent is tenofovir alafenamide. 
     
     
         79 . The method of  claim 77 , wherein the first additional therapeutic agent is tenofovir alafenamide hemifumarate. 
     
     
         80 . The method of  claim 77 , wherein the first additional therapeutic agent is tenofovir alafenamide fumarate.